


This listing of claims will replace all prior versions, and listings, of claims in the application:


**Listing of Claims:**

1. (Original) Compounds of the formula I



in which

X is H,  $-C(=NR^3)-NHR^4$  or Het,



Y is  $-(CH_2)_m-$ ,

Z is NH or  $CH_2$ ,

$R^1$

and  $R^5$  are each, independently of one another, H, A, OH, OA, arylalkyl, Hal,  $-CO-A$ , CN,  $NO_2$ ,  $NHR^3$ , COOA, COOH,  $SO_2A$ ,  $CF_3$  or  $OCF_3$ ,

$R^2$  is in each case, independently of the others, H or A,

$R^3$

and  $R^4$  are each, independently of one another, H, A,  $-CO-A$ ,  $NO_2$  or CN,

A is alkyl having 1-6 carbon atoms,


m is 0, 1, 2, 3, 4, 5 or 6,

n and p are, independently of one another, 1, 2 or 3,


and physiologically acceptable derivatives thereof, in particular salts

and solvates thereof.


2. (Original) Compounds of the formula I according to Claim 1, in which A is methyl, furthermore ethyl, isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl or tert-butyl.
3. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 and 2~~ Claim 1, in which Het is 4-methylpyridin-2-yl, pyridin-2-yl, pyrimidin-2-yl, imidazol-2-yl, benzimidazol-2-yl and hydrogenated derivatives thereof.
4. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 to 3~~ Claim 1, characterised in that R<sup>1</sup> and R<sup>5</sup>, independently of one another, are preferably H, A, CN, NO<sub>2</sub>, Hal or -COA.
5. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 to 3~~ Claim 1, characterised in that R<sup>2</sup> is preferably H or A.
6. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 to 3~~ Claim 1, characterised in that R<sup>3</sup> and R<sup>4</sup>, independently of one another, are preferably H or -COA.
7. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 to 3~~ Claim 1, characterised in that X is H, -C(=NH)-NH<sub>2</sub>, -C(=N-methyl)-NH<sub>2</sub>, 4-methylpyridin-2-yl, pyridin-2-yl, pyrimidin-2-yl, imidazol-2-yl, benzimidazol-2-yl and hydrogenated derivatives thereof.
8. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 to 3~~ Claim 1, characterised in that Y is -(CH<sub>2</sub>)<sub>m</sub>- or




9. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 to 3~~ Claim 1, characterised in that n and p, independently of one another, are 1 or 2.
10. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 to 3~~ Claim 1, characterised in that m is 0, 2 or 4.
11. (Original) Compounds of the formulae I1 to I36:




I1



I2




I3




I4


I5




16




· 17




18




19




110




111




I12




I13




I14




I15




I16




I17




I18




I19




I20




I21




I22




123




124




125




126




127




128




129




130



131




132







I33




I34




I35



I36




12. (Currently Amended) Process for the preparation of compounds of the formula I according to ~~one or more of Claims 1 to 11~~ Claim 1 and salts thereof, characterised in that
- a) a compound of the formula II



II

in which Z, R<sup>1</sup> and n are as defined above, and W is a conventional protecting group or a solid phase used in peptide chemistry,

is reacted with a compound of the formula III



III

in which Y is as defined above, and Q is a suitable protecting group or Het, in the presence of a condensing agent, such as, for example, HATU,

and the protecting groups and/or the solid phase are subsequently removed,

and, where appropriate, the resultant product is, if Q as protecting group is removed, reacted with a suitable guanyl compound, such as, for example, N,N'-bis-BOC-1-guanylpurazole, and, if desired, the remaining protecting groups and/or the solid phase are removed,

or

b) a compound of the formula I is liberated from one of its functional derivatives by treatment with a solvolysing or hydrogenolysing agent,

and/or in that a basic or acidic compound of the formula I is converted into one of its salts by treatment with an acid or base.

13. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 to 14~~ Claim 1 and physiologically acceptable salts or

solvates thereof as therapeutic active ingredients.

14. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 to 11~~ Claim 1 and physiologically acceptable salts or solvates thereof as integrin inhibitors.
15. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 to 11~~ Claim 1 and physiologically acceptable salts or solvates thereof for use in combating diseases.
16. (Currently Amended) Pharmaceutical preparation, characterised by a content of at least one compound of the formula I according to ~~one or more of Claims 1 to 11~~ Claim 1 and/or one of its physiologically acceptable salts or solvates.
17. (Currently Amended) Use of compounds of the formula I according to ~~one or more of Claims 1 to 11~~ Claim 1 and/or physiologically acceptable salts or solvates thereof for the preparation of a pharmaceutical preparation.
18. (Currently Amended) Use of compounds of the formula I according to ~~one or more of Claims 1 to 11~~ Claim 1 and/or physiologically acceptable salts or solvates thereof for the preparation of a pharmaceutical preparation for combating thromboses, cardiac infarction, coronary heart diseases, arteriosclerosis, inflammation, tumours, osteoporosis, infections and restenosis after angioplasty.
19. (Currently Amended) Use of compounds of the formula I according to ~~one or more of Claims 1 to 11~~ Claim 1 and/or physiologically acceptable salts or solvates thereof in pathological processes which are maintained or propagated by angiogenesis.